ABVC BioPharma (ABVC) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing plant-derived drugs and medical devices targeting CNS, oncology, and ophthalmology indications.

• Pipeline includes multiple Phase II clinical trials in the US, Australia, and Taiwan, with plans to partner with large pharma for Phase III and commercialization.

• Subsidiaries BioKey and BioLite provide R&D, manufacturing, and licensing services, with BioKey also engaged in generic drugs and nutraceuticals.

• Recent strategic partnerships and licensing agreements in China and globally for drug development and commercialization.

Financial performance and metrics

• As of May 22, 2025, aggregate market value of public float is $19,622,846.5, with a closing price of $1.38 per share.

• 16,981,593 shares of common stock issued and outstanding; no preferred stock currently outstanding.

• Multiple licensing deals with milestone and royalty payments, including recent agreements with AIBL, FEYE, and OncoX, with partial milestone payments received in 2024.

Use of proceeds and capital allocation

• Net proceeds intended for general corporate purposes, including working capital, debt repayment, licensing milestone payments, and CRDMO expansion.